[PDF][PDF] Comparison of Maximum Permissible Activity of I-131 Determined by Benua and Leeper Method and Blood Absorbed Dose Method in Differentiated Thyroid …
TA Afridi, M Waqar, A Khawar, N Marwat… - … . Appl. An Int. J., no. I …, 2022 - academia.edu
Background: Iodine-131 NaI is the mainstay of treatment in patients with well differentiated
carcinoma. Fixed versus dosimetrically determined doses for iodine therapy are long in …
carcinoma. Fixed versus dosimetrically determined doses for iodine therapy are long in …
Effective half-life of I-131 in patients with differentiated thyroid cancer treated by radioactive I-131
SG Park - Nuclear Medicine and Molecular Imaging, 2008 - pesquisa.bvsalud.org
PURPOSE: Effective half life of I-131 (T (eff)) in patients with differentiated thyroid cancer
treated by I-131 is must-know value for dose calculation and determination of release time …
treated by I-131 is must-know value for dose calculation and determination of release time …
[HTML][HTML] Evaluation of the physical and biological dosimetry methods in iodine-131-treated patients
A Ozdal, T Erselcan, Ö Özdemir… - World journal of …, 2018 - ncbi.nlm.nih.gov
The aim of the study was to compare physical and biological dosimetry methods in iodine-
131 (I-131)-receiving patients. The present study comprised of 47 patients (mean age …
131 (I-131)-receiving patients. The present study comprised of 47 patients (mean age …
Assessment of simplified blood dose protocols for the estimation of the maximum tolerable activity in thyroid cancer patients undergoing radioiodine therapy using …
W Jentzen, A Bockisch… - Journal of Nuclear …, 2015 - Soc Nuclear Med
In high-activity radioiodine therapies for differentiated thyroid cancer, blood dosimetry has
been developed to estimate the maximum tolerable activity (MTA) of 131I that can be safely …
been developed to estimate the maximum tolerable activity (MTA) of 131I that can be safely …
The utility of percent 48-hour whole body retention for modifying empiric amounts of I-131 for the treatment of thyroid carcinoma
D Van Nostrand, F Atkins, K Kulkarni, K Burman… - 2006 - Soc Nuclear Med
1284 Objectives: Although whole body dosimetry can be used to determine the maximum
tolerated activity (MTA) of I-131 to treat metastatic well-differentiated thyroid carcinoma …
tolerated activity (MTA) of I-131 to treat metastatic well-differentiated thyroid carcinoma …
[HTML][HTML] Effect of administrated activity, admission number and TSH level on radiation retention curve of patients taking iodine-131 therapy for differentiated thyroid …
M Moslehi, A Mahmoud-Pashazadeh… - Iranian Journal of …, 2018 - irjnm.tums.ac.ir
Introduction: Retention of I-131 in the body of patients with differentiated thyroid carcinoma
(DTC) has a direct effect on therapeutic outcome of radioiodine therapy. There are several …
(DTC) has a direct effect on therapeutic outcome of radioiodine therapy. There are several …
[PDF][PDF] Theoretical comparison of absorbed dose estimation using dose commitment formula and medical internal radiation dose in radioactive iodine-131 therapy
J Ali, AU Khan, S Ali - Pakistan Journal of Nuclear Medicine, 2020 - researchgate.net
ABSTRACT Background: Radioactive iodine-131 (RAI-131) is used for the treatment and
diagnosis of thyroid disorder. It is commonly used for internal radionuclide therapy of …
diagnosis of thyroid disorder. It is commonly used for internal radionuclide therapy of …
Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer
M Abuqbeitah, M Demir, L Kabasakal… - Nuclear Medicine …, 2018 - journals.lww.com
Aim The development of reliable dosimetry models promotes the individualized therapy
concept toward more success and less complications. This paper evaluates the traditional …
concept toward more success and less complications. This paper evaluates the traditional …
Alternative means of estimating 131I maximum permissible activity to treat thyroid cancer
KJ Nichols, W Robeson, M Yoshida-Hay… - Journal of Nuclear …, 2017 - Soc Nuclear Med
To protect bone marrow from overirradiation, the maximum permissible activity (MPA) of 131I
to treat thyroid cancer is that which limits the absorbed dose to blood (as a surrogate of …
to treat thyroid cancer is that which limits the absorbed dose to blood (as a surrogate of …
One Size Does Not Fit All: The Merit of Absorbed Doses to the Blood in: 131: I Therapy for Differentiated Thyroid Carcinoma
L Fatholahi, F Tabeie, AM Pashazadeh, H Javadi… - Health …, 2015 - journals.lww.com
The amount of 131 I necessary for successful ablation in patients with differentiated thyroid
cancer (DTC) is still subject to debate. This study investigates the relationship of the …
cancer (DTC) is still subject to debate. This study investigates the relationship of the …